{"entity":{"id":"serum-institute-of-india","kind":"company","name":"Serum Institute of India","aka":[],"tldr":"The world's largest vaccine maker by doses, which developed CERVAVAC, India's first home-made HPV vaccine, so that cervical cancer prevention no longer depends on imported shots.","summary":"The Serum Institute of India was founded in 1966 in Pune and makes more vaccine doses than any other company. With support from the Department of Biotechnology it developed CERVAVAC, a quadrivalent HPV vaccine against types 6, 11, 16 and 18 produced in Hansenula polymorpha yeast, indicated for girls and women aged 9 to 26 (cervical, vulvar, vaginal and anal cancer and genital warts) and boys and men aged 9 to 26 (anal cancer and genital warts), given as two doses at 0 and 6 months for ages 9 to 14 and three doses for ages 15 to 26. CERVAVAC received Indian market authorisation in 2022 and was introduced in 2023; published comparisons report immunogenicity non-inferior to established vaccines, and it is the intended supply for India's planned national HPV vaccination programme.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.seruminstitute.com"},{"label":"CERVAVAC product page","url":"https://www.seruminstitute.com/product_ind_cervavac.php"}],"tags":[],"related":[],"cancers":["cervical","head-and-neck"],"sections":["prevention"],"technologies":["hpv-vaccine"],"targets":[],"drugs":["cervavac","gardasil-9"],"companies":[],"institutions":["dbt-india"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-prevention-adoption","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Pune","country":"IN","companyType":"pharma","website":"https://www.seruminstitute.com","founded":1966,"investors":[],"funding":[]},"route":"/companies/serum-institute-of-india/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"section":[{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"}],"technology":[{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/"}],"drug":[{"id":"cervavac","kind":"drug","name":"CERVAVAC (quadrivalent HPV vaccine, India)","route":"/drugs/cervavac/"},{"id":"gardasil-9","kind":"drug","name":"Nonavalent HPV vaccine","route":"/drugs/gardasil-9/"}],"institution":[{"id":"dbt-india","kind":"institution","name":"Department of Biotechnology, Government of India","route":"/institutions/dbt-india/"}],"bottleneck":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/"}],"roadmap":[{"id":"prevention-roadmap","kind":"roadmap","name":"Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers","route":"/roadmaps/prevention-roadmap/"},{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}]}}